GANX · Gain Therapeutics, Inc.
$1.78
-0.07 (-3.78%)
At close · Aug 28
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report.”View the 10-Q filed Aug 11, 2026
Market Cap
$80.74M
Shares
43.64M
Registered funds — mutual funds, ETFs and closed-end funds — whose latest Form N-PORT portfolio report holds this stock, matched by the stock's CUSIP. Each row is one fund position with its size, value and weight in that fund.
Funds holding GANX
12 fund positions| Fund | Ticker | Balance | Value | % of Fund | Side | Reported | Open |
|---|---|---|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND | — | 399,886 | $775,779 | 0.00% | Long | 2026-03-31 | |
| Fidelity Extended Market Index Fund | FSMAX | 207,106 | $403,857 | 0.00% | Long | 2026-05-31 | |
| iShares Micro-Cap ETF | IWC | 144,159 | $292,643 | 0.02% | Long | 2026-06-30 | |
| Fidelity Total Market Index Fund | FSKAX | 57,335 | $111,803 | 0.00% | Long | 2026-05-31 | |
| Fidelity Series Total Market Index Fund | FCFMX | 55,636 | $108,490 | 0.00% | Long | 2026-05-31 | |
| Ultra-Small Company Market Fund | BRSIX | 30,004 | $60,908 | 0.04% | Long | 2026-06-30 | |
| Fidelity Nasdaq Composite Index Fund | FNCMX | 28,629 | $55,827 | 0.00% | Long | 2026-05-31 | |
| 1290 VT Micro Cap Portfolio | — | 9,730 | $19,752 | 0.01% | Long | 2026-06-30 | |
| Victory Extended Market Index Fund | USMIX | 4,249 | $8,031 | 0.00% | Long | 2026-04-30 | |
| iShares Neuroscience and Healthcare ETF | IBRN | 2,048 | $3,871 | 0.07% | Long | 2026-04-30 | |
| Total Stock Market Index Trust | — | 966 | $1,961 | 0.00% | Long | 2026-06-30 | |
| Blackstone Alternative Multi-Strategy Fund | — | 7,200 | $14,616 | 0.00% | Short | 2026-06-30 |
Showing 1–12 of 12 positions
Key facts
CIK
1819411
CUSIP
36269B105
13F (30d)
43 filings
43 filers
Visit website
Investor relations